Testing advanced sequencing methods for diagnosing bacterial infections and antibiotic resistance
Molecular Diagnostics of Bacterial Infections and Antibiotic Resistance in Blood Samples and Rectal Swabs Using Advanced NGS Sequencing Methods
NA · IRCCS Sacro Cuore Don Calabria di Negrar · NCT06322173
This study is testing if advanced DNA sequencing methods can better diagnose bacterial infections and antibiotic resistance in patients compared to the usual lab tests.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | IRCCS Sacro Cuore Don Calabria di Negrar (other) |
| Locations | 1 site (Negrar, Verona) |
| Trial ID | NCT06322173 on ClinicalTrials.gov |
What this trial studies
This project aims to evaluate the effectiveness of next-generation sequencing (NGS) techniques on biological samples, specifically blood and rectal swabs, to diagnose bacterial infections and assess antibiotic resistance. The study will compare the results obtained from NGS with standard microbiological methods currently used in clinical diagnostics. It involves analyzing samples from patients who have undergone blood culture and multi-drug resistant surveillance tests at a specific hospital. The goal is to enhance the accuracy and efficiency of diagnosing bacterial infections.
Who should consider this trial
Good fit: Ideal candidates for this study are patients whose blood culture and multi-drug resistant surveillance tests have been performed at the participating hospital.
Not a fit: Patients without available data on the presence of targeted bacteria or those lacking stored biological samples will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses of bacterial infections and better management of antibiotic resistance in patients.
How similar studies have performed: While the use of NGS in microbiology is gaining traction, this specific application in diagnosing bacterial infections and antibiotic resistance is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Samples of patients for whom blood culture and Multi Drug Resistant (MDR) surveillance tests were carried out in rectal swabs at the IRCCS Sacro Cuore Don Calabria Hospital * Samples for which the Information and consent to the conservation of biological samples for research purposes has been signed at the Tropica Biobank or * Samples for which, after all reasonable efforts, it was not possible to obtain the signature of the Information and consent to the conservation of biological samples for research purposes at the Tropica Biobank (e.g. patients in intensive care, immobilized patients unable to sign or with serious alterations of consciousness). Exclusion criteria: * Absence of data relating to positivity or negativity to the germs of interest * Absence of stored residual material
Where this trial is running
Negrar, Verona
- IRCCS Sacro Cuore Don Calabria hospital — Negrar, Verona, Italy (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Resistance Bacterial